Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:21 AM
Ignite Modification Date: 2025-12-25 @ 3:21 AM
NCT ID: NCT03663205
Eligibility Criteria: Inclusion Criteria: 1. Age 18-75 years old, male or female, signed informed consent form 2. Advanced NSCLC diagnosed by pathological or clinical physicians 3. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1 4. Participants must have ≥ 1 measurable lesion as defined per RECIST v1.1 5. Participants must have no prior systemic chemotherapy for advanced or metastatic NSCLC 6. Life expectancy ≥ 12 weeks 7. Participants must have adequate organ function 8. Male/female is willing to use a highly effective method of birth control Exclusion Criteria: 1. Diagnosed with NSCLC but with epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation 2. Received any approved systemic anticancer therapy within 28 days prior to the initiation of study treatment 3. Received prior treatment with EGFR inhibitors or ALK inhibitors 4. Received prior therapies targeting programmed cell death protein-1 (PD-1) or programmed cell death protein ligand-1 (PD-L1) 5. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases 6. Clinically significant pericardial effusion 7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis 8. Any major surgical procedure ≤ 28 days before randomization 9. Human immunodeficiency virus (HIV) infection 10. Participants with untreated hepatitis B or C virus (HBV/HCV) 11. Active autoimmune diseases or history of autoimmune diseases 12. History of allergic reactions to chemotherapy NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT03663205
Study Brief:
Protocol Section: NCT03663205